.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Precision medicine continues to evolve by identifying unique vulnerabilities in tumor cells. When chromosomal deletions occur, they often remove tumor suppressor genes alongside adjacent passenger genes. This collateral loss creates a state of synthetic lethality. Specifically, the loss of FOCAD, a gene located near CDKN2A and MTAP on chromosome 9p21, induces a critical dependency on the HBS1L/PELO ribosome-rescue complex. To exploit this, researchers developed TNG961, a first-in-class HBS1L molecular glue degrader that offers a potent therapeutic strategy for these genetically defined cancers.
The HBS1L/PELO complex is vital for maintaining translational homeostasis by rescuing stalled ribosomes. In healthy cells, the SKI complex, which includes the FOCAD protein, helps manage aberrant mRNA. However, when FOCAD is deleted, the SKI complex destabilizes, leading to an accumulation of stalled ribosomes. Consequently, these cancer cells become hyper-dependent on HBS1L to survive. By using an HBS1L molecular glue degrader, clinicians can selectively induce proteasomal degradation of this essential rescue factor, leading to translational arrest and cell death.
TNG961 emerged from an intensive medicinal chemistry campaign guided by cryo-EM structures. It promotes a ternary complex between HBS1L and the E3 ligase cereblon, facilitating rapid ubiquitination. Furthermore, preclinical studies demonstrate that oral administration of TNG961 leads to significant tumor regression in various xenograft models. Notably, this HBS1L molecular glue degrader remains effective even in models that have become refractory to PRMT5 inhibitors. This finding is particularly relevant because FOCAD is co-deleted in approximately one-third of MTAP-deleted cancers, providing a secondary line of attack for difficult-to-treat malignancies.
The development of TNG961 signifies a major step forward in targeting mRNA quality control pathways. Because TNG961 is orally bioavailable and highly selective, it minimizes off-target degradation of canonical neosubstrates like IKZF1. Moreover, the high prevalence of 9p21 deletions in solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer, suggests a broad potential patient population. Researchers are now moving toward clinical evaluation to confirm the efficacy and safety of this first-in-class therapeutic in human subjects.
TNG961 acts as a molecular glue that brings HBS1L into proximity with the cereblon E3 ligase complex. This leads to the selective ubiquitination and subsequent proteasomal degradation of HBS1L, disrupting ribosome rescue in FOCAD-deleted cells.
FOCAD loss disrupts the SKI complex, making cells unable to process aberrant mRNA efficiently. This creates a synthetic lethal dependency on the HBS1L/PELO complex for ribosome recycling, which TNG961 exploits to kill tumor cells while sparing healthy tissue.
Yes, preclinical data show that TNG961 induces tumor regression in models that are refractory to PRMT5 inhibitors, suggesting it could be a vital treatment option for patients who have progressed on existing precision therapies.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
TNG961 is a first-in-class HBS1L molecular glue degrader designed to treat FOCAD-deleted cancers by exploiting synthetic lethal dependencies in ribosome res...
4 months ago
A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
